Ian Mudway is a Lecturer in Respiratory Toxicology at King’s College in London. He has been active in air pollution research, participating in Air Quality conferences, speaking out on BBC World News and in the Guardian newspaper, and advising the World Health Organization.
Here, Dr. Henn talks with Dr. Mudway about his recent publication , “Quantifying the magnitude of the oxygen artefact inherent in culturing airway cells under atmospheric oxygen versus physiological levels.”
At what oxygen level should I culture my umbilical cord-derived hematopoietic stem cells? It’s not a question you will hear on Jeopardy, but it is a critically important question.
Hematopoietic stem cells from umbilical cord blood (CB-HSC) have been shown to be beneficial for treating leukemia1,2, neuroblastoma3, and is of great interest for other disease applications. NIH-funded clinical trials listed on clinicaltrials.gov include studies of CB-HSC for immunodeficiencies, autoimmune diseases, sickle cell, cerebral palsy, complications of prematurity, and stroke. However, individual cord blood units often do not have the cell yield needed for a full transplant, requiring the pairing of HLA- partially matched cord blood units for a single transplant4. This presents obvious drawbacks in limiting the numbers of patients that can be treated.
Because room air is assumed to be near 21% oxygen, researchers often report that their room air incubator is as well. However, if you would think about it for a minute, you would realize that this is impossible.
We charge a traditional open room cell culture incubator with CO2 , raising it to 5% or more, to maintain the pH of carbonate buffer-based cell culture media. Room air contains only 0.03 - 0.06% CO2 (or sometimes a little more if your ventilation is poor). Every time the inner incubator door is opened and closed, CO2 is infused to replace what is lost to the room. This necessarily drives the percentage of oxygen down inside the incubator.
Here, we continue the conversation, talking about the leap that researchers have to take to leave their old way of doing things and invest in a system defined by the cells. This conversation was edited for length.
Alicia Henn, Chief Scientific Officer, BioSpherix
In Part One, we talked to Michael Gilkey, CEO of Trailhead Biosystems about the power of Trailhead’s unique combination of robotics, Design of Experiments-based methods, and mathematical modeling to identify the best combinations of reagents for recapitulating cell development in vitro.
Here, we continue the conversation, talking about all the different cell types Trailhead is addressing with their unique platform.